Tissue plasminogen activator glycosylation variants with improve

Details Tissue plasminogen activator glycosylation variants with improve Tissue plasminogen activator glycosylation variants with improve

1995-05-08

1997-03-18

Jacobson, Dian C.

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

424 9463, 435212, 435226, 435 681, A61K 3849, C12N 948, C12N 964

Patent

active

056120290

ABSTRACT:
The invention concerns tissue plasminogen activator (t-PA) variants which are glycosylated at any of positions 103-105, and are devoid of functional carbohydrate structure at position 117 of wild-type human t-PA amino acid sequence. The variants have extended circulatory half-life and substantially retained fibrin binding, or improved in vivo fibrinolytic potency, as compared to wild-type human t-PA.

REFERENCES:
patent: 4752603 (1988-06-01), Collen et al.
patent: 4753879 (1988-06-01), Rosa
patent: 4766075 (1988-08-01), Goeddel et al.
patent: 4772585 (1988-09-01), Sarnoff
patent: 4837022 (1989-06-01), Kakimoto
patent: 4839169 (1989-06-01), Whittle
patent: 4935237 (1990-06-01), Higgins et al.
patent: 4960702 (1990-10-01), Rice et al.
patent: 4968617 (1990-11-01), Johnston et al.
patent: 4980165 (1990-12-01), Isaacs et al.
patent: 5041376 (1991-08-01), Gething et al.
patent: 5108901 (1992-04-01), Anderson et al.
patent: 5112609 (1992-05-01), Johnston et al.
patent: 5232847 (1993-08-01), Edwards et al.
patent: 5242688 (1993-09-01), Burck et al.
patent: 5246850 (1993-09-01), Bennett et al.
patent: 5258180 (1993-11-01), Gill et al.
patent: 5262170 (1993-11-01), Anderson et al.
patent: 5270198 (1993-12-01), Anderson et al.
patent: 5304482 (1994-04-01), Sambrook et al.
patent: 5342616 (1994-08-01), Cohen
patent: 5344773 (1994-09-01), Wei et al.
patent: 5366730 (1994-11-01), Kohnert et al.
patent: 5385732 (1995-01-01), Anderson et al.
patent: 5409699 (1995-04-01), Kohnert et al.
Webster's II New Riverside University Dictionary, ex:The Riverside Publishing Company pp. 126 (1984).
Pharmacia Fine Chemicals Catalogue 84 (1 and 6) (1984).
Agnelli et al., "Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits" Blood 66(2):399-401 (1985).
Ahern et al., "Site-directed mutagenesis in human tissue-plasminogen activator: Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation" Journal of Biological Chemistry 265(10):5540-5545 (1990).
Bennett et al., "Mapping the functional determinants of tissue plasminogen activator" Fibrinolysis, 10th International Congress on Fibrinolysis vol. 4(Suppl. 3):Abstr. No. 37 (1990).
Bennett, W.F. et al., "High resolution analysis of functional determinants on human tissue-type plasminogen activator" Journal of Biological Chemistry 266:5191-5201 (1991).
Berman and Lasky, "Engineering glycoproteins for use as pharmaceuticals" Trends in Biotechnology 3(2):51-53 (1985).
Browne et al., "A Tissue-Type Plasminogen Activator Mutant with Prolonged Clearance In Vivo" Journal of Biological Chemistry 263(4):1599-1602 (1988).
Bugelski, P.J. et al., "Uptake of human recombinant tissue-type plasminogen activator by rat hepatocytes in vivo: an electron microscope autoradiographic study" Throm. Res. 53:287-303 (1989).
Cambier et al., "Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis" J. Cardiovasc. Pharmacol. 11:468 (1988).
Collen et al., "Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits" Blood 71(1):216-219 (Jan. 1988).
Collen et al., "Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model" Thromb. Haemost. 65:174-180 (1991).
Eisenberg et al., "Sustained Fibrinolysis After Administration of t-PA despite its short half-life in the circulation" Thromb. and Haemost. 57(1):35-40 (1987).
Eisert et al., "Bolus treatment regimen of t-PA expedites rate of lysis in vivo without increasing risk of bleeding" Haemostasis (Abstract, 5th Congress of the Society on Thromb. and Haemost. (Feb. 1988) Frankfurt) pp. 85 (114) (1988).
Eisert et al., "Repeated bolus administration of rTPA at 30 minute intervals lyses clots as efficiently as continuous 2 hour infusion" Blood (Supplement) (Abstract (28th Annual Mtg of the Am. Society of Hematol. (Dec. 1986)) 68(5):1208 (1986).
Fu et al., "Disposition of a novel recombinant tissue plasminogen activator, .DELTA.2-89 tpa, in mice" Thrombosis Research 50:33-41 (1988).
Gardell et al., "Isolation, Characterization, and cDNA Cloning of a Vampire Bat Salivary Plasminogen Activator" Journal of Biological Chemistry 264(30):17947-17952 (1989).
Gold and Leinbach, "Prevention of acute reocclusion after thrombolysis with intravenous recombinant tissue plasminogen activator" Tissue Plasminogen Activator in Thrombolytic Therapy, Sobel et al., New York:Dekker vol. Chapter 7:115-130 (1987).
Gold et al., "Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation" Circulation 77(3):670-677 (1988).
Gunzler, W. et al., "The Primary Structure of High Molecular Mass Urokinas from Human Urine The Complete Amino Acid Sequence of the A Chain," Hoppe-Seyler's Z. Physiol. Chem. Bd. 363:S. 1155-1165 (1982).
Haigwood et al., "Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the N-and C-termini" Prot. Engineering 2:611-620 (1989).
Harris, "Second Generation Plasminogen Activators" Protein Engineering 1(6):449-458 (1987).
Higgins and Bennett, "Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis" Ann. Rev. Pharmacol. Toxicol. 30:91-121 (1990).
Holmes, W. et al., "Cloning and Expression of the Gene for Pro-Urokinase in Escherichia Coli ," Bio/Technology 3:923-929 (1985).
Hotchkiss A. et al., "The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator" Thrombosis and Haemostasis 60(2):255-261 (1988).
Hotchkiss et al., "The activity of a single chain rt-PA mutant in a primates and rabbits" Thromb. Haemost. (Abstract only) 58:491 (1987).
Huber and Bode, "Structural Basis of the Activation and Action of Trypsin" Accounts of Chemical Research 11;114-122 (1978).
Johannessen et al., "Fibrin affinity and clearance of t-PA deletion and substitution analogues" Thromb. Haemost. 63:54-59 (1990).
Kalyan et al., "Structure-function analysis with tissue-type plasminogen activator" Journal of Biological Chemistry 263:3971-3978 (1988).
Kasai, S. et al., "Proteolytic Cleavage of Single-chain Pro-urokinase Induces Conformational Change which Follows Activation of the Zymogen and Reduction of Its High Affinity for Fibrin," Journal of Biological Chemistry 260(22):12377-12381 (1985).
Kasai, S. et al., "Thrombolytic Properties of an Inactive Proenzyme Form of Human Urokinase Secreted from Human Kidney Cells," Cell Structure and Function 10:151-159 (1985).
Kassell et al., "Zymogens of Proteolytic Enzymes" Science 180:1022-1027 (1973).
Kaufman et al., "Expression and Amplification of DNA Introduced into Mammalian Cells" Gene Amplification, Cold Spring Harbor Laboratory pp. 245-250 (1982).
Keyt et al., "Slowly clearing mutants of tissue plasminogen activator with conserved fibrinolytic activity" Fibrinolysis, Amsterdam:11th International Congress on Fibrinolysis vol. 6(Suppl. 2):Abstr. No. 64 (1992).
Khan et al., "Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction" Am. J. Cardiol. 65:1051-1056 (1990).
Ladenheim, R.G. et al., "N-Linked Glycosylation Affects the Processing of Mouse Submaxillary Gland Prorenin in Transfected AtT20 Cells" European Journal of Biochemistry 198(2):535-540 (1991).
Larsen et al., "Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat" Blood 73:1842-1850 (1989).
Lau et al., "A modified human tissue plasminogen activator with extended half-life in vivo" Bio/Technology 5:953-958 (1987).
Lau et al., "A modified human tissue plasminogen acti

Affiliated with

Also associated with

Rating

Tissue plasminogen activator glycosylation variants with improve does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tissue plasminogen activator glycosylation variants with improve, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue plasminogen activator glycosylation variants with improve will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1704124